for OWC Pharmaceutical
Execution of an agreement to perform a Safety study of OWC’s soluble tablet versus Sativex®
OWC Pharmaceutical Research Corp. (“OWC”) is happy to announce the execution of a contract with the Souraski Medical Center Fund in Tel Aviv for performing a Single-Dose, Randomized, Crossover Study to compare the Safety, Tolerability and Pharmacokinetics of OWC’s Medical Grade Cannabis – Orally Disintegrating Tablets (MGC-ODT) with Buccal Sativex®, in Healthy Adult Volunteers.
To Our Shareholders
The last year was a critical year in which we laid the foundations for the sustainable success for our Company. We defined our strategy carefully and consolidated our positioning as a company which undertakes the research and development of fully validated medical products and pharmaceuticals based on cannabis.